

# Elena Elefante

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7495463/elena-elefante-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

37  
papers

374  
citations

11  
h-index

18  
g-index

46  
ext. papers

492  
ext. citations

3.1  
avg, IF

3.79  
L-index

#	Paper	IF	Citations
37	One year in review 2022: systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , <b>2022</b> , 40, 4-14	2.2	5
36	Myeloid neoplasms and autoimmune diseases: markers of association. <i>Clinical and Experimental Rheumatology</i> , <b>2022</b> , 40, 49-55	2.2	1
35	Self-Reported Anxiety and Depression in a Monocentric Cohort of Patients With Systemic Lupus Erythematosus: Analysis of Prevalence, Main Determinants, and Impact on Quality of Life.. <i>Frontiers in Medicine</i> , <b>2022</b> , 9, 859840	4.9	0
34	One year in review 2022: systemic lupus erythematosus.. <i>Clinical and Experimental Rheumatology</i> , <b>2022</b> , 40, 4-14	2.2	1
33	Salivary Proteomics Markers for Preclinical Sjögren Syndrome: A Pilot Study. <i>Biomolecules</i> , <b>2022</b> , 12, 738	5.9	1
32	Multicentric study comparing cyclosporine, mycophenolate mofetil and azathioprine in the maintenance therapy of lupus nephritis: 8 years follow up. <i>Journal of Nephrology</i> , <b>2021</b> , 34, 389-398	4.8	6
31	Impact of first wave of SARS-CoV-2 infection in patients with Systemic Lupus Erythematosus: Weighting the risk of infection and flare. <i>PLoS ONE</i> , <b>2021</b> , 16, e0245274	3.7	9
30	Are remission and low disease activity state ideal targets for pregnancy planning in systemic lupus erythematosus? A multicentre study. <i>Rheumatology</i> , <b>2021</b> , 60, 5610-5619	3.9	5
29	How do systemic lupus erythematosus patients with very-long disease duration present? Analysis of a monocentric cohort. <i>Lupus</i> , <b>2021</b> , 30, 439-447	2.6	1
28	Myeloid neoplasms and autoimmune diseases: markers of association. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> ,	2.2	3
27	COVID-19: the new challenge for rheumatologists. One year later. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 203-213	2.2	1
26	One year in review 2021: systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 231-241	2.2	1
25	COVID-19: the new challenge for rheumatologists. One year later. <i>Clinical and Experimental Rheumatology</i> , <b>2021</b> , 39, 203-213	2.2	2
24	The patient's perspective: are quality of life and disease burden a possible treatment target in systemic lupus erythematosus?. <i>Rheumatology</i> , <b>2020</b> , 59, v63-v68	3.9	8
23	Impact of fatigue on health-related quality of life and illness perception in a monocentric cohort of patients with systemic lupus erythematosus. <i>RMD Open</i> , <b>2020</b> , 6,	5.9	11
22	Articular involvement, steroid treatment and fibromyalgia are the main determinants of patient-physician discordance in systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , <b>2020</b> , 22, 241	5.7	5
21	Translation, cultural adaptation and validation of the Italian version of the Brief Index of Lupus Damage: the BILDit. <i>Lupus</i> , <b>2020</b> , 29, 1198-1205	2.6	

20	Sexual dysfunction in Behçet's syndrome. <i>Rheumatology International</i> , <b>2020</b> , 40, 9-15	3.6	5
19	Framingham, ACC/AHA or QRISK3: which is the best in systemic lupus erythematosus cardiovascular risk estimation?. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 602-608	2.2	4
18	One year in review 2020: vasculitis. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38 Suppl 124, 3-14	2.2	1
17	Are patients with systemic lupus erythematosus more prone to result false-positive for SARS-CoV2 serology?. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 577	2.2	3
16	One year in review 2020: systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , <b>2020</b> , 38, 592-601	2.2	3
15	Glucocorticoid withdrawal in systemic lupus erythematosus: are remission and low disease activity reliable starting points for stopping treatment? A real-life experience. <i>RMD Open</i> , <b>2019</b> , 5, e000916	5.9	20
14	Disease activity assessment of rheumatic diseases during pregnancy: a comprehensive review of indices used in clinical studies. <i>Autoimmunity Reviews</i> , <b>2019</b> , 18, 164-176	13.6	27
13	One year in review 2019: vasculitis. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37 Suppl 117, 3-19	2.2	3
12	One year in review 2019: systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , <b>2019</b> , 37, 715-722	2.2	18
11	Biomarkers for Sjögren's syndrome. <i>Biomarkers in Medicine</i> , <b>2018</b> , 12, 275-286	2.3	31
10	Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres. <i>Lupus Science and Medicine</i> , <b>2018</b> , 5, e000274	4.6	6
9	One year in review 2018: systemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 111, 12-32	2.2	7
8	One year in review 2018: systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 763-777	2.2	16
7	Imaging of joints in systemic lupus erythematosus. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36 Suppl 114, 68-73	2.2	4
6	Behçet's syndrome and psychiatric involvement: is it a primary or secondary feature of the disease?. <i>Clinical and Experimental Rheumatology</i> , <b>2018</b> , 36, 125-128	2.2	5
5	One year in review 2017: systemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35 Suppl 103, 5-26	2.2	3
4	One year in review 2017: novelties in the treatment of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2017</b> , 35, 721-734	2.2	21
3	One year in review: systemic vasculitis. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, S1-6	2.2	9

2	One year in review 2016: novelties in the treatment of rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 357-72	2.2	17
1	One year in review 2015: Sjögren's syndrome. <i>Clinical and Experimental Rheumatology</i> , <b>2015</b> , 33, 259-71	2.2	27